Home

Transforming Cancer Monitoring

At Oncobit, we aim to improve patient outcomes with high-precision and cutting-edge cancer monitoring solutions.

Our Mission

Enabling personalized cancer care

We use state-of-the-art technologies to develop cancer-specific monitoring tests and provide physicians with optimal therapy-decision support. Based on a simple blood sample, we offer innovative and robust solutions to closely, precisely and reliably monitor cancer and treatment response. This ensures that patients receive the best possible medical care at optimal cost efficiency.

Learn more about Oncobit

Our Solutions

Specific and sensitive tools for an optimal cancer therapy management

Our solutions provide clinicians with advanced molecular insights for precise cancer monitoring and therapy optimization.

Oncobit™ PM is a data-driven cancer monitoring platform for the sensitive and quantitative detection of specific cancer markers in circulating tumor-derived DNA (ctDNA) from the blood. It consists of cancer specific reagents and a cloud-based analysis software for automatic data interpretation and reporting. This ensures that clinicians receive an unbiased and clear report in a timely manner.

Learn more about our solutions

Our Journey

Loading…

February 2025

Oncobit Achieves ISO 13485 Recertification and Expands IVDR Certification to Cover Additional Indications

We are proud to announce our successful recertification of ISO 13485, and the expansion of our IVDR certification to cover additional indications.

February 2025

Prof. Reinhard Dummer joins Oncobit as Senior Medical Advisor

We are excited to welcome Prof. Reinhard Dummer to Oncobit as Senior Medical Advisor. Prof. Dummer is a highly cited Professor of Dermatology at the University Zurich. He is renowned for his extensive contributions to skin cancer research, particularly in melanoma and non-melanoma skin cancers at the University Hospital Zurich. As Senior Medical Advisor, Prof. Dummer will play a key role in guiding Oncobit’s clinical strategies, and fostering collaborations with leading medical institutions and industry partners.

November 2024

Oncobit closes 1.5M Pre-Series A Financing Round

We are thrilled to announce that we closed a 1.5M CHF Pre-Series A Financing round. A huge thank you to our existing and new investors for supporting our vision of enabling personalized cancer care. The investment will enable us to continue to grow and strengthen our position in the cancer monitoring market.

Oncobit’s tests provide critical decision support in the treatment and monitoring of advanced melanoma patients.

Prof. Dr. med. Reinhard Dummer, Department of Dermatology USZ, Head of the Skin tumor center, Expert for the Comprehensive Cancer Center Zürich